Business
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.“Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are d
About this update from Ocugen, Inc.
[{"type":"image","alt":"Ocugen","displaySize":"","headline":null,"caption":"Ocugen","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":171,"url":"https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GdnYVqy165SQnz1CdcOk_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a","width":300,"height":171}},"lazy":false},{"type":"text","content":"MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.“Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress,” said Dr. Musunuri. “This premier conference is the optimal way to kick off Ocugen’s catalyst-rich 2026 and engage in critical conversations with potential strategic partners and the investment community.”In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will be on site in San Franciso all week to conduct one-on-one meetings highlighting the Company’s business strategy on the path toward filing three BLAs in the next two years including the rolling BLA of OCU400 for retinitis pigmentosa this year.Details regarding the presentation are as follows:Date: Thursday, January 15, 2026Time: 9:45 - 10:25 a.m. PST Location: Colonial Room, MezzanineA live video webcast of the presentation will be available on the events page of the Ocugen investor site. The webcast replay will be available for a limited time following the event.About Ocugen, Inc.Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address...